Regeneron Pharmaceuticals Investor Presentation — June 2020

Document content

CORPORATE PRESENTATION

2NOTE REGARDING FORWARD -LOOKING STATEMENTS

AND NON -GAAP FINANCIAL MEASURES

This presentation includes forward -looking statements thatinvolve risks anduncertainties relating tofuture events andthefuture performance ofRegeneron Pharmaceuticals, Inc.(“Regeneron” orthe“Company”), andactual events orresults may differ materially from

these forward -looking statements .Words such as“anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations ofsuch words, andsimilar expressions areintended toidentify such forward -looking statements, although notallforward -looking statements

contain these identifying words .These statements concern, andthese risks anduncertainties include, among others, theimpact ofSARS -CoV-2(thevirus thathascaused theCOVID -19pandemic) onRegeneron's business anditsemployees, collaborators, suppliers,

and other third parties onwhich Regeneron relies, Regeneron's and itscollaborators’ ability tocontinue toconduct research and clinical programs, Regeneron's ability tomanage itssupply chain, netproduct sales ofproducts marketed byRegeneron and/or its

collaborators (collectively, "Regeneron’s Products"), andtheglobal economy ;thenature, timing, andpossible success andtherapeutic applications ofRegeneron’s Products andRegeneron’s product candidates andresearch andclinical programs now underway or

planned, including without limitation EYLEA® (aflibercept) Injection, Dupixent® (dupilumab ),Libtayo ®(cemiplimab), Praluent® (alirocumab), Kevzara® (sarilumab ),fasinumab ,evinacumab ,garetosmab ,pozelimab ,Regeneron’s oncology programs (including its

costimulatory bispecific portfolio andother therapeutic approaches discussed inthispresentation), Regeneron’s COVID -19antibody program andother earlier -stage product candidates, andtheuseofhuman genetics inRegeneron’s research programs ;theextent to

which theresults from theresearch anddevelopment programs orpreclinical testing conducted byRegeneron oritscollaborators (including theresearch anddevelopment programs andpreclinical testing discussed inthispresentation) may bereplicated inother studies

andmay lead toadvancement ofproduct candidates toclinical trials ortherapeutic applications ;unforeseen safety issues resulting from theadministration ofRegeneron’s Products andproduct candidates inpatients, including serious complications orside effects in

connection with theuseofRegeneron’s product candidates inclinical trials ;thelikelihood andtiming ofpossible regulatory approval andcommercial launch ofRegeneron’s late-stage product candidates andnew indications forRegeneron’s Products, including without

limitation EYLEA, Dupixent, Libtayo ,Praluent, Kevzara, fasinumab ,evinacumab ,REGN -EB3,garetosmab ,pozelimab ,andREGN 1979 ;thelikelihood andtiming ofachieving anyoftheanticipated milestones described inthispresentation ;ongoing regulatory obligations